Centessa Pharmaceuticals (CNTA) on Wednesday filed a registration statement covering the potential sale of its securities from time to time.
The filing covers ordinary shares, American depositary shares, debt securities, warrants, and units.
Net proceeds will be primarily for general corporate purposes, the company said, adding it may also use part of the proceeds to pay interest or principal on debt and/or buy and invest in companies, products and technologies.
Separately, Centessa said Wednesday it has started an underwritten public offering of $150 million of American depositary shares.
The company said it plans to give the underwriters a 30-day option to buy up to an additional $22.5 million of ADSs.
The planned offering is subject to market conditions, and there's no assurance as to whether or when it may be completed, or as to its size or terms, Centessa added.
Comments